Form 4: Alnylam Pharmaceuticals Director Amy Schulman Reports Stock and Option Awards

Director Amy Schulman reports acquisition of stock and option awards in Alnylam Pharmaceuticals.

Summary

• On May 8, 2025, Amy Schulman, a director of Alnylam Pharmaceuticals, reported the acquisition of 775 shares of common stock and options to purchase 1,558 shares of common stock.
• The common stock was acquired through restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan.
• Each RSU represents a contingent right to receive one share of common stock, vesting fully on the earlier of the first anniversary of the grant date or retirement/resignation within 90 days of the anniversary.
• The stock options have an exercise price of $258.35 and also vest fully on the earlier of the first anniversary of the grant date or retirement/resignation within 90 days of the anniversary.
• Following these transactions, Schulman directly owns 11,961 shares of common stock and options to purchase 1,558 shares.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of stock and option awards to a director, indicating standard compensation practices. It doesn't contain any information that would significantly impact investor sentiment positively or negatively.

Positives

• The acquisition of stock and options by a director could be seen as a positive signal, indicating confidence in the company's future performance.

Future Outlook

The vesting of the RSUs and stock options is contingent upon continued service or retirement/resignation within a specific timeframe.

Industry Context

Stock and option awards are a common form of compensation for directors and executives in publicly traded companies, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Equity compensation for board members varies widely across the pharmaceutical industry depending on company size, stage, and performance.
• Comparing Alnylam's director compensation to peers like Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, or Dicerna Pharmaceuticals (acquired by Novo Nordisk) would provide a benchmark.
• Typical equity grants for directors in similar biotech companies range from $100,000 to $500,000 annually, often in a mix of stock options and restricted stock units.

Stakeholder Impact

• The granting of stock options and RSUs aligns the director's interests with those of shareholders, incentivizing them to work towards increasing shareholder value.

Key Dates

Keywords

Alnylam Pharmaceuticals, Amy Schulman, Director, Stock Options, RSUs, Beneficial Ownership, Form 4